Pages that link to "Q33564501"

The following pages link to Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis (Q33564501):

Displaying 11 items.

• Quantitative gait analysis as a method to assess mechanical hyperalgesia modulated by disease-modifying antirheumatoid drugs in the adjuvant-induced arthritic rat (Q28221343) (← links)
• Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? (Q33565496) (← links)
• Sulfasalazine: a review of its use in the management of rheumatoid arthritis (Q36237544) (← links)
• Medical management of rheumatoid arthritis (Q40403535) (← links)
• Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis (Q40432257) (← links)
• Disease-modifying antirheumatic drugs. Potential effects in older patients (Q40970113) (← links)
• Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs (Q41258424) (← links)
• A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis (Q46052611) (← links)
• A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis. (Q53993832) (← links)
• The effect of auranofin and sulphasalazine therapy on circulating levels of interleukin 6 in rheumatoid arthritis patients (Q70867169) (← links)
• Sulphasalazine in the treatment of pauciarticular-onset juvenile chronic arthritis (Q72670687) (← links)